Bausch Health Companies Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $10.27B | $9.63B | $8.76B | $8.12B | $8.43B | $8.03B | $8.60B | $8.38B |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | — | — | — | — |
| SG&A Expense | $3.44B | $3.30B | $2.92B | $2.63B | $2.62B | $2.37B | $2.55B | $2.47B |
| Operating Income | $1.81B | $1.55B | $963.0M | $454.0M | $450.0M | $676.0M | $-203.0M | $-2.38B |
| Operating Margin | 17.7% | 16.1% | 11.0% | 5.6% | 5.3% | 8.4% | -2.4% | -28.4% |
| Interest Expense | $1.60B | $1.39B | $1.33B | $1.46B | $1.43B | $1.53B | $1.61B | $1.69B |
| Pretax Income | $367.0M | $167.0M | $-390.0M | $-129.0M | $-1.02B | $-934.0M | $-1.84B | $-4.15B |
| Income Tax Expense | $247.0M | $239.0M | $221.0M | $83.0M | $-87.0M | $-375.0M | $-54.0M | $-10.0M |
| Net Income | $157.0M | $-46.0M | $-592.0M | $-225.0M | $-948.0M | $-560.0M | $-1.79B | $-4.14B |
| Net Margin | 1.5% | -0.5% | -6.8% | -2.8% | -11.2% | -7.0% | -20.8% | -49.5% |
| EPS (Basic) | $0.42 | $-0.13 | $-1.62 | $-0.62 | $-2.64 | $-1.58 | $-5.08 | $-11.81 |
| EPS (Diluted) | $0.42 | $-0.13 | $-1.62 | $-0.62 | $-2.64 | $-1.58 | $-5.08 | $-11.81 |
| Shares Outstanding (Basic) | 370.9M | 368.0M | 364.9M | 362.0M | 358.9M | 355.0M | 352.1M | 351.3M |
| Shares Outstanding (Diluted) | 375.0M | 368.0M | 364.9M | 362.0M | 358.9M | 355.0M | 352.1M | 351.3M |
| Dividends Per Share | — | — | — | — | — | — | — | — |